What is QV Bioelectronics?
Founded in 2018, QV Bioelectronics is at the forefront of developing novel electrotherapy devices aimed at treating specific types of brain tumors. The company's technological approach focuses on leveraging electrical stimulation to target and disrupt cancerous cells, offering a potentially less invasive and more effective treatment modality. This strategic capital infusion is expected to accelerate the company's research and development pipeline, moving its innovative solutions closer to clinical application and patient benefit.
How much funding has QV Bioelectronics raised?
QV Bioelectronics has raised a total of $7.8M across 2 funding rounds:
Other Financing Round
$2.5M
Grant
$5.4M
Other Financing Round (2023): $2.5M with participation from Fink Family Law Offices, Catapult Ventures, Northern Gritstone, and Science Angel Syndicate
Grant (2026): $5.4M led by GM&C Life Sciences Fund, UK Research & Innovation, NIHR, and Empirical Ventures
Key Investors in QV Bioelectronics
GM&C Life Sciences Fund
GM&C Life Sciences Fund, managed by Catapult Ventures, is a venture capital fund focused on seed and early-stage investments in life sciences within the Greater Manchester and Cheshire & Warrington region, supporting innovative businesses.
UK Research & Innovation
UK Research & Innovation is a UK-based non-departmental public body that fosters an environment for research and innovation, partnering with various entities to maintain the UK's global leadership in science.
Empirical Ventures
Empirical Ventures is a European venture capital firm specializing in early-stage, deep-tech ventures, with a focus on Life Sciences, Advanced Materials, and other cutting-edge technologies addressing global challenges.
What's next for QV Bioelectronics?
With the recent influx of major strategic investment and substantial overall capital, QV Bioelectronics is poised for significant growth and development. The company is likely to focus on scaling its operations, expanding its research team, and progressing its electrotherapy devices through rigorous clinical trials. This funding context suggests a transition from early-stage development to a scaling phase, with an emphasis on market penetration and establishing its technology as a viable therapeutic option in the competitive neuro-oncology landscape. Future endeavors will likely involve strategic partnerships and further validation of their technology's efficacy and safety.
See full QV Bioelectronics company page
